Reducing Constipation in Parkinson’s, Step by Step - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Reducing Constipation in Parkinson’s, Step by Step

A 3-month walking program was associated with improved constipation symptoms and lower Parkinson’s disease severity scores in a small uncontrolled pre–post study

  • By

  • Henry Thomas

  • March 30, 2026

  • 2 min

Share

Objective:

To evaluate the impact of increased daily walking activity on constipation symptoms and overall disease severity in patients with Parkinson’s disease.

Approach:
    Key Findings:
    • Constipation scores improved immediately after the walking program and remained improved at the 3-month follow-up.
    • Overall Parkinson’s disease severity, as measured by the Unified Parkinson’s Disease Rating Scale, declined following the intervention.
    • Improvements in nonmotor and activities-of-daily-living domains were observed immediately after the intervention.
    Interpretation:

    Walking may serve as a practical self-management strategy for alleviating gastrointestinal symptoms and reducing overall disease burden in Parkinson’s disease.

    Limitations:
    • Small sample size limits generalizability.
    • Lack of a control group restricts causal interpretation.
    Conclusion:

    Further research through larger randomized controlled trials is necessary to confirm the findings regarding walking's benefits for constipation and disease severity in Parkinson’s disease.

    Sources:

Original Source(s)

Reducing Constipation in Parkinson’s, Step by Step

  • by Henry Thomas

  • March 30, 2026

Related Content

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

CSF Biomarker May Support Lewy Body Diagnosis

A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls

How Safe Are FDA-Cleared AI Tools?

“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."